Compare Agilent Technologies Inc (A) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.00B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Agilent Technologies Inc is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| A | ZBH | |
|---|---|---|
Market Cap | $42.00B | $18.65B |
Sector | Health | Health |
52-Week High | $157.20 | $107.71 |
52-Week Low | $110.24 | $79.58 |
Enterprise Value | $43.55B | $25.72B |
Dividend Yield | 0.69% | 0.98% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
